Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis

References

• Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379(9):856–868.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331.
   PubMed Web of Science ®Google Scholar
• Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37(2):108–114.
   PubMedGoogle Scholar
• Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem langerhans cell histiocytosis. Blood. 2013;121(25):5006–5014.
   PubMed Web of Science ®Google Scholar
• Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015;126(12):1415–1423.
   PubMed Web of Science ®Google Scholar
• Weitzman S, Braier J, Donadieu J, et al. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the histiocyte society. Pediatr. Blood Cancer. 2009;53(7):1271–1276.
   PubMed Web of Science ®Google Scholar
• Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015;169(5):711–718.
   PubMed Web of Science ®Google Scholar
• Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of langerhans cell histiocytosis in adults. Blood. 2022;139(17):2601–2621.
   PubMed Web of Science ®Google Scholar
• Go RS, Jacobsen E, Baiocchi R, et al. Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(11):1277–1303.
   PubMed Web of Science ®Google Scholar
• Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with langerhans cell histiocytosis: recommendations from an expert panel on behalf of euro-histio-net. Orphanet J Rare Dis. 2013;8:72.
   PubMed Web of Science ®Google Scholar
• Badalian-Very G, Vergilio J-A, Degar BA, et al. Recurrent BRAF mutations in langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–736.
   PubMed Web of Science ®Google Scholar
• Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAFV600E -mutated adult langerhans cell histiocytosis. Oncologist. 2020;25(12):1001–1004.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384–388.
   PubMed Web of Science ®Google Scholar
• Reichle A, Vogt T, Kunz-Schughart L, et al. Anti-inflammatory and angiostatic therapy in chemorefractory multisystem langerhans' cell histiocytosis of adults. Br J Haematol. 2005;128(5):730–732.
   PubMed Web of Science ®Google Scholar
• Heudobler D, Luke F, Vogelhuber M, et al. Anakoinosis: correcting aberrant homeostasis of cancer tissue-going beyond apoptosis induction. Front Oncol. 2019;9:1408.
   PubMed Web of Science ®Google Scholar
• Heudobler D, Rechenmacher M, Luke F, et al. Clinical efficacy of a novel therapeutic principle. Front Pharmacol. 2018;9:1357.
   PubMed Web of Science ®Google Scholar
• Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of langerhans cells in langerhans cell histiocytosis. Blood. 2001;97(5):1241–1248.
   PubMed Web of Science ®Google Scholar
• Heudobler D, Klobuch S, Thomas S, et al. Cutaneous leukemic infiltrates successfully treated with biomodulatory therapy in a rare case of therapy-related high risk MDS/AML. Front Pharmacol. 2018;9:1279.
   PubMed Web of Science ®Google Scholar
• Thomas S, Schelker R, Klobuch S, et al. Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia. Haematologica. 2015;100(1):e4-6–e6.
   PubMed Web of Science ®Google Scholar
• Walter B, Schrettenbrunner I, Vogelhuber M, et al. Pioglitazone, etoricoxib, interferon-alpha, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med Oncol. 2012;29(2):799–805.
   PubMed Web of Science ®Google Scholar
• Hart C, Vogelhuber M, Hafner C, et al. Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial. J Eur Acad Dermatol Venereol. 2016;30(11):e119–e121.
   PubMed Web of Science ®Google Scholar
• Walter I, Schulz U, Vogelhuber M, et al. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. Med Oncol. 2017;34(12):192.
   PubMed Web of Science ®Google Scholar
• Vogelhuber M, Feyerabend S, Stenzl A, et al. Biomodulatory treatment of patients with castration-resistant prostate cancer: a phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan. Cancer Microenviron. 2015;8(1):33–41.
   PubMedGoogle Scholar
• Heudobler D, Schulz C, Fischer JR, et al. A randomized phase II trial comparing the concerted activity of pioglitazone, clarithromycin and metronomic low-dose chemotherapy to single-agent nivolumab in patients with advanced non–small-cell lung cancer treated in second or further line (ModuLung). Front. Pharmacol. 2021;12:218.
   Web of Science ®Google Scholar
• Lüke F, Harrer DC, Menhart K, et al. Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin's disease. Front Pharmacol. 2021;12:599561.
   PubMed Web of Science ®Google Scholar
• Coras B, Hafner C, Reichle A, et al. Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. Arch Dermatol. 2004;140(12):1504–1507.
   PubMedGoogle Scholar
• Vogt T, Hafner C, Bross K, et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer. 2003;98(10):2251–2256.
   PubMed Web of Science ®Google Scholar
• Donadieu J, Piguet C, Bernard F, et al. A new clinical score for disease activity in langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43(7):770–776.
   PubMed Web of Science ®Google Scholar
• Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer. 2004;101(10):2247–2256.
   PubMed Web of Science ®Google Scholar
• Brown RE. The NF-kappaB pathway and the successful application of anti-inflammatory and angiostatic therapy in langerhans' cell histiocytosis. Br J Haematol. 2005;130(1):147–148.
   PubMed Web of Science ®Google Scholar
• Brown RE. Brief communication: morphoproteomic analysis of osteolytic langerhans cell histiocytosis with therapeutic implications. Ann Clin Lab Sci. 2005;35(2):131–136.
   PubMed Web of Science ®Google Scholar
• Pavlakovic H, Von Schütz V, Rössler J, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int. J. Cancer. 2001;92(5):756–760.
   PubMed Web of Science ®Google Scholar
• Heudobler D, Rechenmacher M, Luke F, et al. Peroxisome proliferator-activated receptors (PPAR) gamma agonists as master modulators of tumor tissue. IJMS. 2018;19(11):3540.
   Google Scholar
• Nencioni A, Grunebach F, Zobywlaski A, et al. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol. 2002;169(3):1228–1235.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Gavrilyuk V, Landreth GE, et al. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem. 2003;85(2):387–398.
   PubMed Web of Science ®Google Scholar
• Brown RE. Cyclo-oxygenase-2 in the osteolytic lesions of langerhans cell histiocytosis. Med. Pediatr. Oncol. 2000;34(4):311–311.
   PubMedGoogle Scholar
• Reichle A, Grassinger J, Bross K, et al. C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomark Insights. 2007;1:87–98.
   PubMedGoogle Scholar
• Yap R, Veliceasa D, Emmenegger U, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res. 2005;11(18):6678–6685.
   PubMed Web of Science ®Google Scholar
• Biziota E, Briasoulis E, Mavroeidis L, et al. Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells. Anticancer Drugs. 2016;27(3):216–224.
   PubMed Web of Science ®Google Scholar